When he first stepped into the field of glycoproteomics, particularly the potential of truncated O-glycans as cancer targets, Constantine Theodoropulos, CEO of Go Therapeutics Inc., said the reaction from peers was less than encouraging. Read More
The “showdown” at the American Society of Clinical Oncology (ASCO) meeting foreseen by one analyst between breast cancer drugs from Gilead Sciences Inc. and Astrazeneca plc with partner Daiichi Sankyo Co. Ltd. didn’t quite materialize. Read More
Five-year survival rates for people with metastatic colorectal cancer haven’t budged much in recent decades but new data presented at the American Society of Clinical Oncology’s annual conference pushed the boundary enough to be notable. Read More
The world’s biggest cancer-focused conference began June 3 as more than 40,000 attendees are expected at the American Society of Clinical Oncology’s (ASCO) annual gathering. The conference is being held in live in Chicago and is also available virtually. Among the more than 2,500 abstract presentations in about 120 subject subcategories are potential breakthroughs in treating non-small-cell lung cancer from Immutep Ltd., Cullinan Oncology Inc. and Surface Oncology Inc. Each company has seen upticks in their stock value, some as much as 10%, during the week as the conference approached and their data are presented. Read More
I-Mab Biopharma Co. Ltd. chief medical officer John Hayslip said the firm is “moving forward at our best speed” in tandem with partner Shanghai Junshi Biosciences Co. Ltd. to produce a diagnostic test that could be used in further clinical work with anti-CD73 antibody uliledlimab, for which results from an ongoing phase II trial were disclosed May 26. Read More
Shanghai Henlius Biotech Inc.’s anti-PD-1 monoclonal antibody serplulimab has generated positive data in a phase III trial as a first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). Read More
Affibody AB and its development partners, Acelyrin Inc. and Inmagene Biopharmaceuticals Co. Ltd., are accelerating plans to move izokibep into phase III studies in psoriatic arthritis following better-than-expected phase II efficacy combined with an apparently clean safety profile. Read More
Although the death toll in the U.S. is nearing 1 million lives lost, signs continue to suggest that an end is in sight for the COVID-19 pandemic, the most disruptive global health crisis in a century. Read More
Cstone Pharmaceuticals Co. Ltd. has begun trading again on the Hong Kong exchange after trading was halted on April 1 following investigations over questionable investments during the company’s year-end audit for 2021. Read More
Abliva AB has gone above its market capitalization to raise the money it needs to start a phase II/III trial of KL-1333 for the treatment of primary mitochondrial disease. Read More
New and updated preclinical and clinical data presented by biopharma firms at the American Society of Clinical Oncology annual meeting, including: Antengene, Dizal, Harbour Biomed, I-Mab, Immutep, Inxmed, Kazia, Seagen, Takeda, Transcenta. Read More
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Ampio, Athersys, Biovaxys Technology, Cocrystal, GSK, Tetra Bio-Pharma Australia, Immedica, Moderna, Orphanpacific, Pfizer, Scineuro, Takeda, Transcenta, Vaxart. Read More
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Eisai, Foresee, Hutchmed, Iaso, Innovent Biologics, J Ints Bio, Mezzion, Revive, Takeda, United. Read More
